Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Negative Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Cancer
Interventions: DRUG: Pembrolizumab|DRUG: Cyclophosphamide
Sponsor: UNC Lineberger Comprehensive Cancer Center
Collaborators: Merck Sharp & Dohme LLC